Redhill Biopharma
RDHL
14 hedge funds and large institutions have $270K invested in Redhill Biopharma in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 4 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
4.06% less ownership
Funds ownership: 10.14% → 6.08% (-4.1%)
13% less funds holding
Funds holding: 16 → 14 (-2)
30% less capital invested
Capital invested by funds: $386K → $270K (-$116K)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$41.2K |
| 2 |
Lido Advisors
Los Angeles,
California
|
+$10.2K |
| 3 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$7.97K |
| 4 |
Citigroup
New York
|
+$4.04K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$323 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YAG
Yorkville Advisors Global
Mountainside,
New Jersey
|
-$211K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$11.3K |
| 3 |
SG
StoneX Group
New York
|
-$10.8K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$9.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$670 |
RDHL Hedge Fund Activity: Q2 2026 in Review
14 institutional investors reported a position in Redhill Biopharma (RDHL) for Q2 2026, worth a combined $270K — down 30% from $386K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of RDHL and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 5 added.
The largest buyer was Citadel Advisors, adding an estimated $41.2K. The largest seller was Yorkville Advisors Global, cutting an estimated $211K.
- 14 institutional investors held Redhill Biopharma (RDHL) as of Q2 2026, down from 16 in Q1 2026.
- Funds reported $270K of Redhill Biopharma stock for Q2 2026, down 30% quarter-over-quarter.
- 2 funds opened new Redhill Biopharma positions in Q2 2026 and 4 closed out, a net change of -2 holders.
- The largest Redhill Biopharma buyer in Q2 2026 was Citadel Advisors, an estimated $41.2K added.
- The largest Redhill Biopharma seller in Q2 2026 was Yorkville Advisors Global, an estimated $211K sold.
Based on aggregated 13F filings for Q2 2026.